REinfection in COVID-19 Estimation of Risk
The primary objective of this study is to estimate the risk of reinfection with SARS-CoV-2 healthcare workers (HCWs) who had a first episode of PCR-confirmed COVID-19.
The secondary objectives are:
- To study the kinetics of HCWs’ SARS-CoV-2 antibody and specific T-cell responses.
- To compare the SARS-CoV-2 antibody kinetics and T-cell responses in asymptomatic and symptomatic HCWs with and without reinfection with COVID-19.
- To explore viral loads and viral strains when/if reinfected.
- To obtain information on SARS-CoV-2 antibodies and specific T cell responses for HCWs who were previously infected and not previously infected with COVID-19 and who receive the COVID-19 vaccine (any manufacturer).
Overview
- Acronym
- RECOVER
- Investigators
-
General Design
- Study design
- Other : There are two study designs in RECOVER: cohort (phase 1) and cross-sectional (phase 2).
- Start - End Year
- 2020 - 2023
- General Information on Follow Up (profile, frequency)
-
Phase 1
The Phase 1 COVID-19 group has regularly scheduled biweekly follow-ups and is also followed up at 3, 6, 9, and 12 months post-enrollment. In the event of possible reinfection, participants are followed up twice: 2-4 and 28-42 days post symptom onset. Unvaccinated participants have an additional scheduled follow-up at 18 months post-enrollment.Phase 2
The Phase 2 COVID-19 subgroup is followed up after each vaccination: 7, 14, 28, 45 (± 25), 90, 180, and 365 days post-dose 1 and 7, 14, 28, and 57 (± 30) days post-dose 2.The Phase 2 COVID-19 naïve group is followed up after each vaccination: 7, 14, 28, 29 (± 2), 90, 180, and 365 days post-dose 1 and 7, 14, 28, and 35 (± 5) days post-dose 2.
Extension I
A subset of participants from Phase 1 and Phase 2 are followed up once at 0 to 7 days pre-vaccination (any dose), once post-vaccination (any dose), and twice at 18 and 24 months.Extension II A subset of participants from Phase 1 and Phase 2 are followed up twice post-reinfection: at 6 and 12 months.
- Recruitment Target
-
- Individuals
- Number of Participants
- 609
- Number of Participants with Biological Samples
- 609
- Supplementary information about number of participants
-
Extension I data collections: 320 participants
Extension II data collections: 45 (recruitment ongoing)
- Supplementary Information
-
The RECOVER study implemented a 12-month extension from the initial protocol. A subset of participants from phases 1 and 2 participated in the Extension I and II data collections.
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Papers
Racine É, Boivin G, Longtin Y, et al,. The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Influenza Other Respir Viruses. 2022;16(5):916-925.
PUBMED 35510653Nantel S, Bourdin B, Adams K, et al,. Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine. Front Immunol. 2022;13:930252.
PUBMED 36311736Timeline
Populations
The population is composed of healthcare workers that have tested positive for COVID-19 and that, upon initial infection, are symptomatic or not.
Selection Criteria
- Countries
-
- Canada
- Canadian Provinces
-
- Quebec
- Health Status
-
Participants must have had a PCR-confirmed COVID-19 infection prior to enrollment.
- Other Criteria
-
Exclusion criteria:
- At the time of recruitment are no longer working in a healthcare setting or have been furloughed as a preventive measure;
- Are not fluent in French or English;
- Have no access to a cell phone or internet, as follow-up will be done through text messages and emails.
- Are participating in a clinical trial for preventive treatment of COVID-19 {e.g., high dose Vitamin D (>2000IU/day or ≥10,000IU/wk), colchicine}, who are still on treatment upon recruitment. Can be included if taken for other reasons.
- Have received a COVID-19 vaccine prior to their enrolment in the study.
- Supplementary Information about selection criteria
-
Of 570 participants, the majority are female (83.0%) and Caucasian (79.3%). The median age is 42. Most worked in acute-care hospitals (54.1%) or public long-term care facilities (24.4%). The most commonly reported profession is nurse/paramedic (40.4%), followed by patient care attendant (12.8%) and physician/medical resident (11.8%).
Sources of Recruitment
- Specific Population
-
- Members of an association
- Participants from Existing Studies
-
- Santé Publique du Québec (INSPQ) (G. De Serres) case-control study
- Supplementary Information
-
Recruitment is done in vaccine study centers (MUHC/CHUSJ Vaccine Center), with additional recruitment in hospitals (CHUM, JGH, MUHC) or CHSLDs, near/where participants work.
Participants are also recruited from the large case-control study conducted by the INSPQ.
Sample Size
- Number of Participants
- 570
- Number of Participants with Biological Samples
- 570
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | RECOVER - Phase 1 COVID-19 group - Enrollment |
|
|
2020 (August) | 2021 (April) |
| 1 | RECOVER - Phase 1 COVID-19 group - Reinfection |
|
|
2020 (August) | 2022 (April) |
| 2 | RECOVER - Phase 1 COVID-19 group - Biweekly follow-up |
|
2020 (August) | 2022 (April) | |
| 3 | RECOVER - Phase 1 COVID-19 group - Follow-up 3 months |
|
|
2020 (November) | 2021 (July) |
| 4 | RECOVER - Phase 1 COVID-19 group - Follow-up 6 months |
|
|
2021 (February) | 2021 (October) |
| 5 | RECOVER - Phase 1 COVID-19 group - Follow-up 9 months |
|
|
2021 (May) | 2022 (January) |
| 6 | RECOVER - Phase 1 COVID-19 group - Follow-up 12 months |
|
|
2021 (August) | 2022 (April) |
| 7 | RECOVER - Phase 1 COVID-19 group - Follow-up 18 months |
|
|
2022 (February) | 2022 (October) |
| 8 | RECOVER - Phase 1 COVID-19 group - Extension I pre-vaccination |
|
|
2021 (August) | 2023 (April) |
| 9 | RECOVER - Phase 1 COVID-19 group - Extension I post-vaccination |
|
|
2021 (August) | 2023 (April) |
| 10 | RECOVER - Phase 1 COVID-19 group - Extension I follow-up 18 months |
|
|
2022 (February) | 2022 (October) |
| 11 | RECOVER - Phase 1 COVID-19 group - Extension I follow-up 24 months |
|
|
2022 (August) | 2023 (April) |
| 12 | RECOVER - Phase 1 COVID-19 group - Extension II 6 months post-reinfection |
|
|
2022 (June) | Ongoing |
| 13 | RECOVER - Phase 1 COVID-19 group - Extension II 12 months post-reinfection |
|
|
2022 (December) | Ongoing |
Selection Criteria
- Countries
-
- Canada
- Canadian Provinces
-
- Quebec
- Health Status
-
Participants must have had a PCR-confirmed COVID-19 infection prior to enrollment.
Participants included in this study are selected based on their reported symptomatology at the time of infection and their serostatus at enrollment in the study.
- Other Criteria
-
Participants must be healthcare workers from phase 1 of the RECOVER study. They are selected if their blood samples are available before and after vaccination.
- Supplementary Information about selection criteria
-
Symptomatic participants are matched with asymptomatic participants based on their sex, age, ethnicity, and times of infection and vaccination.
Sources of Recruitment
- Participants from Existing Studies
-
- REinfection in COVID-19 Estimation of Risk (RECOVER)
- Supplementary Information
-
Participants are recruited from the Phase 1 COVID-19 group of the RECOVER study.
Sample Size
- Number of Participants
- 25
- Number of Participants with Biological Samples
- 25
Data Collection Events
Selection Criteria
- Countries
-
- Canada
- Canadian Provinces
-
- Quebec
- Health Status
-
- Participants must not have any history of SARS-CoV-2 infection nor the presence of anti-N or anti-RBD antibodies against SARS-CoV-2 at recruitment.
- Other Criteria
- Participants must be health care workers.
Sources of Recruitment
- Specific Population
-
- Members of an association
Sample Size
- Number of Participants
- 39
- Number of Participants with Biological Samples
- 39
Data Collection Events
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
Areas of Information Collected per per Population and Data Collection Event
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|